clinical

Cheryl Guttman Krader is a contributor to Dermatology Times, Ophthalmology Times, and Urology Times.

Articles

The development of a novel AI-based algorithm aims to improve risk prediction for diabetic eye disease.



From ETDRS to EviRed: Eyeing a new artificial intelligence-based algorithm

Cheryl Guttman is a medical writer based in Deerfield, Ill.

Insights into the pathophysiology of diabetic macular edema are providing a basis for therapeutic interventions.


DME strategies directed by knowledge of mechanisms 

Multiple challenges remain for diabetic macular edema with unmet needs to improve treatment outcomes, speed of treatment benefit, and the duration of response.



What an intravitreal integrin antagonist may bring to DME

Three risk-related baseline factors identified by this analysis may be associated with a potential need for injections.

Post hoc analysis: Protocol V provides more practical DME guidance for clinicians

A study including data from about 42,000 eyes found diabetic retinopathy (DR) severity is a risk factor for the progression of diabetic eye disease. Other findings support the idea that genetic factors influence the development of proliferative DR versus diabetic macular edema. 



Research suggests course of diabetic eye disease influenced by genetic factors

Study highlights the role of demographic and socioeconomic characteristics as contributors to disease- and treatment-related disparities among patients with diabetic macular edema.

Identifying gaps in anti-VEGF treatment among minorities with DME

Videos

A panel of experts in ophthalmology and optometry review the diagnosis and treatment of diabetic eye disease including emerging agents in the field.

Updates in DME, diabetic retinopathy

Results support further research investigating transforming growth factor-β-Induced Gene Human Clone 30 (BIGH3).

Exploring pathogenic cytokines as biomarkers for DME

The benefit is robust across a variety of demographics and baseline disease characteristics, according to data.

Aflibercept broadly effective for reducing DR severity in post-hoc analysis 

Study offers a real-world scenario of a very specific, but frequent and crucial aspect of the care of patients with diabetes, suggests clinician


Researchers advocate for intraoperative intravitreal steroid during cataract surgery in DME eyes

Visual acuity outcomes at 6 months’ post-treatment were similar, regardless of the use of anti-VEGF therapy. 

Probe of IRIS Registry shows anti-VEGF injections leading treatment for PDR 

Researchers advocate for intraoperative intravitreal steroid during cataract surgery in patients with DME.

Managing the challenge of cataract surgery in eyes with diabetic macular edema

Study explores correlations between functional and structural tests 

Identifying biomarkers to predict diabetic retinopathy progression

The number of patients with retinal diseases is steadily increasing in the United States, according to a retrospective study presented during ARVO 2020.

AMD, DED most common retinal conditions in the United States

Patents gained less vision in clinical practice than patients on clinical trials 

Clinical trial outcomes for macular edema don’t translate to ‘real-world’ settings  

Reductions in macular retinal nonperfusion after anti-VEGF treatment with aflibercept are correlated with improvements in BCVA and central retinal thickness in patients with DR/DME, according to a post-hoc analysis of the VISTA dataset, said Charles C. Wykoff, MD, PhD, during ARVO 2020.

VISTA subanalysis: Macular RNP and clinical outcomes 

Rates of anxiety and depression increased but were not necessarily tied to disease severity

Study explores mental health issues in patients with diabetic retinopathy

A retrospective study found that in both patients with type 2 diabetes and non-diabetics, average central macular thickness was lower in Asians than Caucasians. Why is this significant for clinicians?

Considering ethnicity-related differences in macular thickness among diabetics

Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.

ASRS 2020: AsclepiX lead candidate holds potential for wet AMD, DME, RVO

The results of the Protocol T Extension Study underscore the need for methods to improve long-term visual gains in eyes with diabetic macular edema, according to Dante Pieramici, MD, on behalf of the DRCR Retina Network, during the American Society of Retina Specialists 2020 Virtual Annual Meeting. 

Diabetic Macular Edema